ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-3 Study
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore the benefit of the prasugrel monotherapy without
aspirin as compared with the 1-month dual therapy with aspirin and prasugrel in terms of
reducing bleeding events after percutaneous coroanry intervention (PCI) using cobalt-chromium
everolimus-eluting stents (CoCr-EES, XienceTM) in patients with high bleeding risk or under
the acute coronary syndrome patients.